Azeezat M. Lawal

FDA investigator

Appears on 8 documents from 2023 to 2025, mostly at sites in Maryland. Most often cites responsibilities of quality control unit (21 CFR 211.22).

8
Documents on file
3.8
Observations per 483
2023
First seen
2025
Most recent

What they cite most

From 30 observations

Activity by year

2023: 1, 2024: 4, 2025: 3

Where

Maryland 4 · Virginia 2 · New Jersey 1 · Pennsylvania 1

Is Azeezat M. Lawal coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

8 documents, newest first
FirmOpen
483 Fareva Richmond, Inc.May 23, 2025 · Henrico, Virginia
483 EMINENT Services CorporationApr 28, 2025 · FREDERICK, Maryland
483 C-Care LLCFeb 27, 2025 · Linthicum Heights, Maryland
483 Genus Lifesciences Inc.Dec 13, 2024 · Allentown, Pennsylvania
483 Hikma Pharmaceuticals USA Inc.Jun 12, 2024 · Cherry Hill, New Jersey
483 Eisai Inc.Apr 9, 2024 · Baltimore, Maryland
483 ChemPacific CorporationFeb 15, 2024 · Baltimore, Maryland

About this profile

What does Azeezat M. Lawal inspect?

Azeezat M. Lawal appears on 8 documents on file covering 8 sites, mostly in Maryland.

What do they cite most often?

21 CFR 211.22 (responsibilities of quality control unit), followed by 21 CFR 211.192 and 21 CFR 211.67.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Azeezat M. Lawal is dated May 23, 2025.